Nanjing Hicin Pharmaceutical Co.,Ltd. (China)

Nanjing Hicin Pharmaceutical Co., Ltd. is a high-tech enterprise located in Nanjing Economic and Technological Development Zone. The company was established in 2003 and specializes in pharmaceutical research, production, and marketing. They have GMP-standard workshops for lyophilized powder injections, small volume injections, cephalosporin powder injections, solid preparations, and raw materials. Their product range includes cardiovascular, digestive, endocrine, anti-infective, and immune-related areas, with over 60 representative varieties. They have introduced several essential clinical products to the market, such as torasemide for injection, cefotiam for injection, adenosine monophosphate for injection, ganciclovir sodium for injection, ceftriaxone sodium for injection, tigecycline for injection, and lansoprazole for injection. The company has a 9,600 square meter Hicin New Drug R&D Center in Jiangsu Life Science and Technology Innovation Park, with a research team consisting of doctors and masters. They also maintain extensive project collaborations with renowned domestic and international pharmaceutical research institutions such as China Pharmaceutical University, following a path of "production, learning, and research" joint innovation. They have registered multiple raw materials and formulation products with market potential, forming a beneficial cycle of development, reserves, and production. With a total area of 108 acres and a registered capital of 120 million yuan, the company has the production capacity of 30 million vials of cephalosporin powder injections and 45 million vials of lyophilized powder injections, making it one of the major anti-infective and lyophilized drug production bases in Jiangsu Province. In 2013, the company acquired Zhenjiang Derui Pharmaceutical Co., Ltd., extending its industrial chain to pharmaceutical raw materials and intermediates. The raw materials are exported to Europe, America, Japan, and other regions, solidifying the foundation for the sustainable development of Hicin Pharmaceutical. In 2013, the company completed its transformation into a joint-stock company. They are establishing a modern corporate governance structure, with a management model centered around the "Shareholders' Meeting, Board of Directors, and Supervisory Board." On January 12, 2017, the company successfully listed on the ChiNext board of the Shenzhen Stock Exchange, achieving a combination of the real economy and capital operation. Hicin Pharmaceutical has established and improved a nationwide sales network system, with 28 offices across the country and nearly a thousand terminal promotion and customer service personnel. Their high-quality products, professional sales team, specialized academic promotion capabilities, and comprehensive sales service system have earned the company a good reputation. The company has been awarded honors such as "National Torch Program Key High-tech Enterprise," "High-growth Small and Medium-sized Enterprise in Jiangsu Province," "Advanced Enterprise in Industry-University-Research Cooperation," "Advanced Enterprise in Technological Innovation," "Labor and Social Security Integrity Enterprise," "Informationization-driven Industrialization Demonstration Enterprise," "Contract-honoring and Credit-keeping Enterprise," "Advanced Unit in Energy Conservation and Emission Reduction in Nanjing," and "Excellent Private Enterprise" by government departments multiple times. Adhering to the core values of "cultivating the pharmaceutical industry and serving the country with technology," Hicin Pharmaceutical regards "creating health and protecting all beings" as its mission and aims to become a top 100 enterprise and a century-old brand. They strive to become a new Hicin that is scaled, capitalized, and internationalized, standing proudly on the banks of the Yangtze River in the pharmaceutical industry.